Skip to main content
SpringerLink
Log in

Tumorschmerztherapie

Basistherapie und Behandlung des Durchbruchschmerzes

Cancer pain management

Basic therapy and treatment of breakthrough pain

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Der Schmerz Aims and scope Submit manuscript

Zusammenfassung

Schmerzen bei Tumorerkrankungen sind eine große Belastung für die Patienten und führen zu einer maßgeblichen Einschränkung ihrer Lebensqualität. Grundlage der Therapie der chronischen Schmerzen ist die orale Gabe lang wirksamer Zubereitungen der verschiedenen Analgetika nach festem Zeitschema. Neben dem chronischen Schmerz leiden etwa 60% der Krebspatienten jedoch zusätzlich an Durchbruchschmerzen. Für diese Attacken stehen schnell und kurz wirksame Zubereitungen hochpotenter Opioide zur Verfügung. Entscheidend für die Wahl des richtigen Analgetikums sind eine umfassende Anamneseerhebung sowie die Kenntnis der vorliegenden Schmerzform(en).

Abstract

Cancer pain imposes a great burden on patients and results in considerable constraints limiting their quality of life. The basic treatment for chronic pain consists in oral administration of long-acting preparations of various analgesic agents according to a set schedule. In addition to chronic pain, however, about 60% of cancer patients also suffer from breakthrough pain. Rapid-onset and short-acting preparations of highly potent opioids are available for the management of these attacks. To choose the correct analgesic agent, it is essential to take a comprehensive medical history and be aware of the different forms of pain present.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Arzneimittelkommission der Deutschen Ärzteschaft (2007) Empfehlung zur Therapie von Tumorschmerzen. Arzneiverordnung Praxis 34 [Sonderheft 1]

  2. Beck AT, Ward CH, Mendelson M et al. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571

    CAS  PubMed  Google Scholar 

  3. Bonica JJ, Wall PD, Melzack R (1985) Textbook of pain. Livingstone, Edinburgh New York

  4. Cain DM, Wacnik PW, Eikmeier L et al. (2001) Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2: 15–23

    Article  CAS  PubMed  Google Scholar 

  5. Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82: 263–274

    Article  CAS  PubMed  Google Scholar 

  6. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129–138

    CAS  PubMed  Google Scholar 

  7. De Conno F, Ripamonti C, Saita L et al. (1995) Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13: 1004–1008

    Google Scholar 

  8. De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378–384

    Article  Google Scholar 

  9. Diener KM (1996) Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 53: 1917–1927

    CAS  PubMed  Google Scholar 

  10. Elsner F, Radbruch L, Sabatowski R et al. (1999) Switching opioids to transdermal fentanyl in a clinical setting. Schmerz 13: 273–278

    Article  CAS  PubMed  Google Scholar 

  11. Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3: 38–44

    Article  PubMed  Google Scholar 

  12. Hanks GW, Portenoy RK, Mac Donald N, Forbes K (1998) Difficult pain problems. In: Doyle D, Hanks GW, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 454–477

  13. Honore P, Luger NM, Sabino MA et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521–528; Erratum in: Nat Med (2000) 6: 838

    Google Scholar 

  14. Deutsche Krebsgesellschaft (2002) Leitlinie medikamentöse Schmerztherapie. Interdisziplinäre kurz gefasste Leitlinien der Deutschen Krebsgesellschaft, der Deutschen Gesellschaft für Palliativmedizin, der Deutschen Gesellschaft zum Studium des Schmerzes und der Deutschen Interdisziplinären Vereinigung für Schmerztherapie. Kurzgefasste Interdisziplinäre Leitlinien. 3. Aufl.

  15. Lichtor JL, Sevarino FB, Joshi GP et al. (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 89: 732–738

    Article  CAS  PubMed  Google Scholar 

  16. Lugo RA, Kern SE (2002) Clinical pharmacokinetics of Morphine. J Pain Palliative Care Pharmacother 16: 5–18

    Article  Google Scholar 

  17. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2: 201–209

    Article  CAS  PubMed  Google Scholar 

  18. Marinangeli F, Ciccozzi A, Leonardis M et al. (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27: 409–416

    Article  CAS  PubMed  Google Scholar 

  19. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425–432

    Article  CAS  PubMed  Google Scholar 

  20. Mercadante S, Radbruch L, Caraceni A et al. (2002) Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94: 832–839

    Article  PubMed  Google Scholar 

  21. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273–281

    Article  CAS  PubMed  Google Scholar 

  22. Portenoy RK, Payne R, Coluzzi P et al. (1999) Oral transmucosal Fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303–312

    Article  CAS  PubMed  Google Scholar 

  23. Radbruch L, Loick G, Kiencke P et al. (1999) Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 18: 180–187

    Article  CAS  PubMed  Google Scholar 

  24. Radbruch L, Nauck F (2002) European Association for Palliative Care (EAPC): morphine and alternative opioids in cancer pain: the EAPC recommendations. Schmerz 16: 186–193

    Article  CAS  PubMed  Google Scholar 

  25. Radbruch L, Elsner F (2004) Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 53: 23–29

    Article  CAS  PubMed  Google Scholar 

  26. Rees E (2002) The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs 8: 304–308

    PubMed  Google Scholar 

  27. Streisand JB, Varvel JR, Stanski DR et al. (1991) Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75: 223–229

    Article  CAS  PubMed  Google Scholar 

  28. Streisand JB, Busch MA, Egan TD et al. (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88: 305–309

    Article  CAS  PubMed  Google Scholar 

  29. Svendsen KB, Andersen S, Arnason S et al. (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9: 195–206

    Article  PubMed  Google Scholar 

  30. Taylor DR, Webster LR, Chun SY et al. (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal Fentanyl Citrate (OTFC®, ACTIQ®). Pain Med 8: 281–288

    Article  PubMed  Google Scholar 

  31. Zeppetella G, O’Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20: 87–92

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Vortragstätigkeit für Analgetikafirmen, u. a. Fa. Cephalon, Fa. Mundipharma, Fa. Janssen-Cilag, unabhängige Präsentation und produktneutrale Darstellung der Inhalte.

Author information

Authors and Affiliations

  1. Abteilung Palliativmedizin, Georg-August-Universität Göttingen,Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    F. Nauck & N. Eulitz

Authors
  1. F. Nauck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Eulitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Nauck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nauck, F., Eulitz, N. Tumorschmerztherapie. Schmerz 21, 359–372 (2007). https://doi.org/10.1007/s00482-007-0572-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00482-007-0572-1

Schlüsselwörter

Keywords

Search

Navigation